Nuvation Bio Inc (NUVB) Stock AnalysisNUVBNuvation Bio Inc

Nuvation Bio Inc. is a global oncology company. The Company is focused on tackling cancer treatment. Its diverse pipeline includes taletrectinib (IBTROZI), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor, and a drug-drug conjugate (DDC) program. IBTROZI is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor. Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), which is detected in various tumors, including gliomas. Its platform leverages its drug discovery and chemistry expertise to find the minimum target binding sites of drug X and drug Y and fuse them together, while maintaining activity. Its DDCs are designed to selectively bind to intracellular as well as surface cell membrane targets that are expressed more highly in specific target tissues and to potently deliver anti-cancer warheads to these target tissues. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Nuvation Bio Inc is a good buy right now due to its current price of $6.66, which is significantly below the analyst price target of $20 from RBC Capital, suggesting a potential upside of 200%. Additionally, the company has shown a remarkable revenue growth trajectory, with Q1 2026 revenue reported at $83.2 million, indicating strong market performance and confidence in its cancer drug pipeline.